Grace Kho Dy

Suggest Changes
Learn More
BACKGROUND Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune(More)
7513 Background: Based on preclinical data of additive cytotoxicity with sorafenib (S) and pemetrexed (PEM), this randomized phase II study was done to evaluate the safety and efficacy of the(More)